EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.